Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?

By Orio Francesco   Palomba Stefano   Cascella Teresa   Tauchmanovà Libuse   Nardo Luciano G.   Di Biase Sebastiano   Labella Donato   Russo Tiziana   Savastano Silvia   Tolino Achille   Zullo Fulvio   Colao Annamaria   Lombardi Gaetano  

Reproductive BioMedicine Online, Vol. 10, Iss. 2, 2005-02 ,pp. : 289-292

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Cardiovascular Risk in the Different Phenotypes of Polycystic Ovary Syndrome

By  

Current Pharmaceutical Design, Vol. 22, Iss. 36, 2016-10 ,pp. : 5547-5553

Bentham Science Publishers

Access to resources Recommend Favorite

Plasminogen Activator Inhibitor-1

By  

Current Medicinal Chemistry, Vol. 11, Iss. 17, 2004-09 ,pp. : 2323-2334

Bentham Science Publishers

Access to resources Recommend Favorite

Effects of Altered Plasminogen Activator Inhibitor-1 Expression on Cardiovascular Disease

By  

Current Drug Targets, Vol. 12, Iss. 12, 2011-11 ,pp. : 1782-1789

Bentham Science Publishers

Access to resources Recommend Favorite

The oral insulin sensitiser INS-1 improves ovulation and has beneficial cardiovascular effects in lean women with polycystic ovary syndrome

By  

Inpharma, Vol. 1, Iss. 1245, 2000-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite